Brainstorm Cell Therapeutics Inc. (BCLI)
OTCMKTS · Delayed Price · Currency is USD
0.5800
0.00 (0.00%)
Feb 6, 2026, 4:00 PM EST

BCLI Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
5.857.0410.6910.879.39.36
Research & Development
5.054.6510.7513.9615.2422.33
Operating Expenses
10.911.6921.4424.8224.5431.68
Operating Income
-10.9-11.69-21.44-24.82-24.54-31.68
Interest Expense
-0.41-0.08-0.28---0.13
Interest & Investment Income
---0.550.08-
Other Non Operating Income (Expenses)
0.460.154.53---
Pretax Income
-10.85-11.62-17.19-24.28-24.46-31.81
Net Income
-10.85-11.62-17.19-24.28-24.46-31.81
Net Income to Common
-10.85-11.62-17.19-24.28-24.46-31.81
Shares Outstanding (Basic)
853222
Shares Outstanding (Diluted)
853222
Shares Change (YoY)
78.11%74.87%17.99%0.91%21.22%36.25%
EPS (Basic)
-1.37-2.31-5.99-9.97-10.14-15.99
EPS (Diluted)
-1.37-2.31-5.99-9.97-10.20-15.99
Free Cash Flow
-7.28-9.09-20.48-19.35-26.6-35.57
Free Cash Flow Per Share
-0.92-1.81-7.13-7.95-11.03-17.88
EBITDA
-10.69-11.45-21.17-24.54-24.28-31.47
D&A For EBITDA
0.20.240.270.290.260.22
EBIT
-10.9-11.69-21.44-24.82-24.54-31.68
Source: S&P Global Market Intelligence. Standard template. Financial Sources.